464 related articles for article (PubMed ID: 29164420)
1. BRCAsearch: written pre-test information and BRCA1/2 germline mutation testing in unselected patients with newly diagnosed breast cancer.
Nilsson MP; Törngren T; Henriksson K; Kristoffersson U; Kvist A; Silfverberg B; Borg Å; Loman N
Breast Cancer Res Treat; 2018 Feb; 168(1):117-126. PubMed ID: 29164420
[TBL] [Abstract][Full Text] [Related]
2. High patient satisfaction with a simplified BRCA1/2 testing procedure: long-term results of a prospective study.
Nilsson MP; Nilsson ED; Borg Å; Brandberg Y; Silfverberg B; Loman N
Breast Cancer Res Treat; 2019 Jan; 173(2):313-318. PubMed ID: 30311024
[TBL] [Abstract][Full Text] [Related]
3. A clinically structured and partnered approach to genetic testing in Trinidadian women with breast cancer and their families.
Donenberg T; George S; Ali J; Bravo G; Hernandez K; Sookar N; Ashing KT; Narod SA; Akbari MR; Hurley J
Breast Cancer Res Treat; 2019 Apr; 174(2):469-477. PubMed ID: 30515680
[TBL] [Abstract][Full Text] [Related]
4. Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Nilsson MP; Winter C; Kristoffersson U; Rehn M; Larsson C; Saal LH; Loman N
Fam Cancer; 2017 Apr; 16(2):187-193. PubMed ID: 28120249
[TBL] [Abstract][Full Text] [Related]
5. Written pretest information and germline BRCA1/2 pathogenic variant testing in unselected breast cancer patients: predictors of testing uptake.
Nilsson MP; Nilsson ED; Silfverberg B; Borg Å; Loman N
Genet Med; 2019 Jan; 21(1):89-96. PubMed ID: 29875420
[TBL] [Abstract][Full Text] [Related]
6. Genetic testing in women with early-onset breast cancer: a Traceback pilot study.
Augustinsson A; Nilsson MP; Ellberg C; Kristoffersson U; Olsson H; Ehrencrona H
Breast Cancer Res Treat; 2021 Nov; 190(2):307-315. PubMed ID: 34529195
[TBL] [Abstract][Full Text] [Related]
7. Targeted sequencing of BRCA1 and BRCA2 across a large unselected breast cancer cohort suggests that one-third of mutations are somatic.
Winter C; Nilsson MP; Olsson E; George AM; Chen Y; Kvist A; Törngren T; Vallon-Christersson J; Hegardt C; Häkkinen J; Jönsson G; Grabau D; Malmberg M; Kristoffersson U; Rehn M; Gruvberger-Saal SK; Larsson C; Borg Å; Loman N; Saal LH
Ann Oncol; 2016 Aug; 27(8):1532-8. PubMed ID: 27194814
[TBL] [Abstract][Full Text] [Related]
8. Strategies for recruitment of relatives of BRCA mutation carriers to a genetic testing program in the Bahamas.
Trottier M; Lunn J; Butler R; Curling D; Turnquest T; Royer R; Akbari MR; Donenberg T; Hurley J; Narod SA
Clin Genet; 2015 Aug; 88(2):182-6. PubMed ID: 25060751
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 and BRCA2 Mutation Testing in Young Women With Breast Cancer.
Rosenberg SM; Ruddy KJ; Tamimi RM; Gelber S; Schapira L; Come S; Borges VF; Larsen B; Garber JE; Partridge AH
JAMA Oncol; 2016 Jun; 2(6):730-6. PubMed ID: 26867710
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of Germline Genetic Testing Criteria in a Hospital-Based Series of Women With Breast Cancer.
Yadav S; Hu C; Hart SN; Boddicker N; Polley EC; Na J; Gnanaolivu R; Lee KY; Lindstrom T; Armasu S; Fitz-Gibbon P; Ghosh K; Stan DL; Pruthi S; Neal L; Sandhu N; Rhodes DJ; Klassen C; Peethambaram PP; Haddad TC; Olson JE; Hoskin TL; Goetz MP; Domchek SM; Boughey JC; Ruddy KJ; Couch FJ
J Clin Oncol; 2020 May; 38(13):1409-1418. PubMed ID: 32125938
[TBL] [Abstract][Full Text] [Related]
11. BRCA1/2 testing in newly diagnosed breast and ovarian cancer patients without prior genetic counselling: the DNA-BONus study.
Høberg-Vetti H; Bjorvatn C; Fiane BE; Aas T; Woie K; Espelid H; Rusken T; Eikesdal HP; Listøl W; Haavind MT; Knappskog PM; Haukanes BI; Steen VM; Hoogerbrugge N
Eur J Hum Genet; 2016 Jun; 24(6):881-8. PubMed ID: 26350514
[TBL] [Abstract][Full Text] [Related]
12. Comprehensive Proteomic Profiling-derived Immunohistochemistry-based Prediction Models for BRCA1 and BRCA2 Germline Mutation-related Breast Carcinomas.
Vos S; Elias SG; van der Groep P; Smolders YH; van Gils CH; van Diest PJ
Am J Surg Pathol; 2018 Sep; 42(9):1262-1272. PubMed ID: 29979200
[TBL] [Abstract][Full Text] [Related]
13. Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Sharma P; Klemp JR; Kimler BF; Mahnken JD; Geier LJ; Khan QJ; Elia M; Connor CS; McGinness MK; Mammen JM; Wagner JL; Ward C; Ranallo L; Knight CJ; Stecklein SR; Jensen RA; Fabian CJ; Godwin AK
Breast Cancer Res Treat; 2014 Jun; 145(3):707-14. PubMed ID: 24807107
[TBL] [Abstract][Full Text] [Related]
14. Post-mortem testing; germline BRCA1/2 variant detection using archival FFPE non-tumor tissue. A new paradigm in genetic counseling.
Petersen AH; Aagaard MM; Nielsen HR; Steffensen KD; Waldstrøm M; Bojesen A
Eur J Hum Genet; 2016 Aug; 24(8):1104-11. PubMed ID: 26733283
[TBL] [Abstract][Full Text] [Related]
15. Model-based predictions of BRCA1/2 mutation status in breast carcinoma patients treated at an academic medical center.
Shannon KM; Lubratovich ML; Finkelstein DM; Smith BL; Powell SN; Seiden MV
Cancer; 2002 Jan; 94(2):305-13. PubMed ID: 11900216
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of telephone genetic counselling to facilitate germline BRCA1/2 testing in women with high-grade serous ovarian cancer.
Tutty E; Petelin L; McKinley J; Young MA; Meiser B; Rasmussen VM; Forbes Shepherd R; James PA; Forrest LE
Eur J Hum Genet; 2019 Aug; 27(8):1186-1196. PubMed ID: 30962500
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp Z; Turnbull A; Yost S; Seal S; Mahamdallie S; Poyastro-Pearson E; Warren-Perry M; Eccleston A; Tan MM; Teo SH; Turner N; Strydom A; George A; Rahman N
JAMA Netw Open; 2019 May; 2(5):e194428. PubMed ID: 31125106
[TBL] [Abstract][Full Text] [Related]
18. Finding all BRCA pathogenic mutation carriers: best practice models.
Hoogerbrugge N; Jongmans MC
Eur J Hum Genet; 2016 Sep; 24 Suppl 1(Suppl 1):S19-26. PubMed ID: 27514840
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of deleterious BRCA1 and BRCA2 germline mutations in arab breast and ovarian cancer patients.
Alhuqail AJ; Alzahrani A; Almubarak H; Al-Qadheeb S; Alghofaili L; Almoghrabi N; Alhussaini H; Park BH; Colak D; Karakas B
Breast Cancer Res Treat; 2018 Apr; 168(3):695-702. PubMed ID: 29297111
[TBL] [Abstract][Full Text] [Related]
20. A pilot study investigating feasibility of mainstreaming germline BRCA1 and BRCA2 testing in high-risk patients with breast and/or ovarian cancer in three tertiary Cancer Centres in Ireland.
McVeigh TP; Sweeney KJ; Brennan DJ; McVeigh UM; Ward S; Strydom A; Seal S; Astbury K; Donnellan P; Higgins J; Keane M; Kerin MJ; Malone C; McGough P; McLaughlin R; O'Leary M; Rushe M; Barry MK; MacGregor G; Sugrue M; Yousif A; Al-Azawi D; Berkeley E; Boyle TJ; Connolly EM; Nolan C; Richardson E; Giffney C; Doyle SB; Broderick S; Boyd W; McVey R; Walsh T; Farrell M; Gallagher DJ; Rahman N; George AJ
Fam Cancer; 2023 Apr; 22(2):135-149. PubMed ID: 36029389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
